Sulfadiazine

CHEMBL439 Phase 4 Zugelassen Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
250.3 g/mol
LogP
-0.1
Phase
4

A sulfonamide antibiotic used primarily to treat toxoplasmosis — a parasitic infection that can be life-threatening in people with HIV or weakened immune systems — typically in combination with pyrimethamine. It is also used to prevent rheumatic fever recurrence and to treat certain other bacterial infections.

Molekularmasse

250,2800 g/mol

LogP

-0,10

TPSA

106,00 Ų

Lipinski-Regel der Fünf

Bestanden

Therapeutische Bereiche

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D-Struktur

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Nc1ccc(S(=O)(=O)Nc2ncccn2)cc1

InChI

InChI=1S/C10H10N4O2S/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10/h1-7H,11H2,(H,12,13,14)

Molecular Formula

C10H10N4O2S

HBD / HBA

2 / 6

Rotierbare Bindungen

3

Schwere Atome

17

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

A sulfonamide antibiotic used primarily to treat toxoplasmosis — a parasitic infection that can be life-threatening in people with HIV or weakened immune systems — typically in combination with pyrimethamine. It is also used to prevent rheumatic fever recurrence and to treat certain other bacterial infections.

Yes, Sulfadiazine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL439. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5215. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.